All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), Ipilimumab (10 mg/kg) vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EORTC 18071, 2015 0.72 [0.58; 0.89]
0.72 [0.58 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable deaths (OS) (extension)detailed results EORTC 18071, 2015 0.73 [0.64; 0.83]
0.73 [0.64 ; 0.83 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFSdetailed results EORTC 18071, 2015 0.76 [0.63; 0.91]
0.76 [0.63 ; 0.91 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS (extension)detailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
0.75 [0.63 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS/DFSdetailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
0.75 [0.63 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable AE (any grade)detailed results EORTC 18071, 2015 7.53 [3.17; 17.90]
7.53 [3.17 ; 17.90 ] EORTC 18071, 2015 1 0% 945 NA not evaluable AE (grade 3-4)detailed results EORTC 18071, 2015 0.11 [0.08; 0.17]
0.11 [0.08 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE (any grade)detailed results EORTC 18071, 2015 14.40 [10.07; 20.60]
14.40 [10.07 ; 20.60 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.27 [14.14; 45.18]
25.27 [14.14 ; 45.18 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE leading to death (grade 5)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
10.16 [0.55 ; 186.52 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE leading to discontinuation (any grade)detailed results EORTC 18071, 2015 21.35 [13.41; 33.97]
21.35 [13.41 ; 33.97 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 39.14 [5.34; 286.74]
39.14 [5.34 ; 286.74 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.54 [6.16; 105.87]
25.54 [6.16 ; 105.87 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.70 [5.84; 312.15]
42.70 [5.84 ; 312.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 22.61 [8.20; 62.34]
22.61 [8.20 ; 62.34 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 57.44 [7.90; 417.44]
57.44 [7.90 ; 417.44 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 44.19 [2.67; 732.31]
44.19 [2.67 ; 732.31 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results EORTC 18071, 2015 18.45 [1.07; 319.15]
18.45 [1.07 ; 319.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash TRAE (grade 3-4)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
10.16 [0.55 ; 186.52 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.00 [2.53; 697.02]
42.00 [2.53 ; 697.02 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
0.04 [0.01 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Cough AE (grade 3-4)detailed results Out of scale EORTC 18071, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
0.06 [0.01 ; 0.46 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
0.26 [0.18 ; 0.37 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
0.05 [0.03 ; 0.10 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
0.04 [0.01 ; 0.11 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pruritus AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.07; 0.26]
0.14 [0.07 ; 0.26 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pyrexia AE (grade 3-4)detailed results EORTC 18071, 2015 0.21 [0.08; 0.56]
0.21 [0.08 ; 0.56 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.03; 0.15]
0.06 [0.03 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Vomiting AE (grade 3-4)detailed results EORTC 18071, 2015 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Weight decreased AE (grade 3-4)detailed results EORTC 18071, 2015 0.02 [0.00; 0.16]
0.02 [0.00 ; 0.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-16 08:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 558
